{"text": ["GlaxoSmithKline\u2019s", "Revenues", "in", "4Q17", "Rose", "1%", "Year-over-Year"], "created_at": "2018-02-16 21:34:07"}
{"text": ["How", "Cosentyx", "Resolves", "Enthesitis", "in", "Psoriatic", "Arthritis", "Patients"], "created_at": "2018-02-16 20:35:08"}
{"text": ["Novartis\u2019s", "Cosentyx", "May", "Emerge", "as", "a", "Leading", "Psoriasis", "Drug"], "created_at": "2018-02-16 19:05:02"}
{"text": ["Novartis", "May", "Sell", "U.S.", "Generic", "Pill", "Business", "Amid", "Industry", "Struggles"], "created_at": "2018-02-16 18:55:00"}
{"text": ["Novartis\u2019s", "Cosentyx", "Emerged", "as", "Multi-Blockbuster", "Therapy", "in", "2017"], "created_at": "2018-02-16 17:33:27"}
{"text": ["Novartis", "readies", "to", "auction", "U.S.", "generic", "pills", "business", "-", "sources"], "created_at": "2018-02-16 16:41:16"}
{"text": ["Merck\u2019s", "Human", "Vaccines", "Business", "in", "4Q17"], "created_at": "2018-02-16 15:31:05"}
{"text": ["Roche", "(RHHBY)", "to", "Acquire", "Flatiron", "Health", "for", "$1.9", "Billion"], "created_at": "2018-02-16 15:25:12"}
{"text": ["Roche", "(RHHBY)", "to", "Acquire", "Flatiron", "Health", "for", "$1.9", "Billion"], "created_at": "2018-02-16 15:25:12"}
{"text": ["How", "Did", "Pfizer\u2019s", "Legacy", "Established", "Products", "Segment", "Perform", "in", "2017?"], "created_at": "2018-02-16 12:30:18"}
{"text": ["The", "Swiss", "Stock", "Market", "Extends", "Recovery", "And", "Finishes", "Week", "With", "A", "Gain"], "created_at": "2018-02-16 12:30:00"}
{"text": ["The", "Swiss", "Stock", "Market", "Extends", "Recovery", "And", "Finishes", "Week", "With", "A", "Gain"], "created_at": "2018-02-16 12:30:00"}
